Blistex acquires $20 mil. Stri-Dex acne line from Bayer.
This article was originally published in The Rose Sheet
Executive Summary
BLISTEX ADDING $20 MIL. STRI-DEX ACNE BRAND to its OTC business with the acquisition of the line from Bayer. The purchase of the Stri-Dex acne treatment line from Bayer's Consumer Care division, announced March 11, gives Oakbrook, Ill.-based Blistex an 8.1% dollar share, or a fourth place slot, in the $254 mil. combined acne remedy market in U.S. food, drug and mass merchandise outlets, according to Chicago-based Information Resources, Inc. data for the 52 weeks ended Jan. 28.